MDMiguel Debono

Miguel Debono

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Miguel Debono has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy and Tolerability of Metyrapone in Mild Autonomous Cortisol Secretion: Real‐World Findings From Clinical Practice

    by Simon Berry, Ahmed Iqbal, John Newell‐Price, Miguel Debono

    Objective: Mild autonomous cortisol secretion (MACS) is associated with increased cardiometabolic risk factors including hypertension, type 2 diabetes and dyslipidaemia. By using evening doses of metyrapone, a short‐acting 11‐β hydroxylase inhibitor, it has been shown that it is possible to reset the abnormal circadian cortisol rhythm in MACS. This study aimed to evaluate the tolerability and impact of this approach on cardiometabolic outcomes in patients with MACS. Design: We conducted a single‐centre retrospective, longitudinal review of patients with MACS who received evening metyrapone (250–500 mg at 6 PM and 250 mg at 10 PM) to evaluate adverse events, tolerability, and cardiometabolic outcomes (systolic and diastolic blood pressure, HbA1c, weight and non‐HDL cholesterol) at 6 months, compared to controls. Age and sex‐matched controls were identified from patients with adrenal incidentalomas and non‐suppressed serum cortisol following 1 mg overnight dexamethasone suppression testing. Results: Fifteen patients and 15 matched controls were identified. Over 6 months there were no adrenal crises. Metyrapone was stopped in 2/15 patients in view of side effects. In the metyrapone group compared to controls, there were significant decreases in systolic blood pressure (−17.7 (SE 5.8) vs. +8.7 (5.7)mmHg, p = 0.008, n = 9) and diastolic blood pressure (−9.9 (4.2) vs. +3.0 (3.6)mmHg, p = 0.024). The differences between groups for HbA1c, weight and non‐HDL cholesterol were not statistically significant. Conclusion: Evening metyrapone was associated with significant reductions in systolic and diastolic blood pressure in patients with MACS, without causing adrenal insufficiency, indicating its potential safe clinical utility. A well‐powered, controlled, prospective study is needed to validate these findings and comprehensively investigate the broader metabolic outcomes.


  • Open Access

    Diagnostic performance of morning serum cortisol for glucocorticoid weaning in children and adults

    by Muhammad Fahad Arshad, Aneeq Ahmed, Sian Beddows, Isaac Marsh, Arwa Mullamitha, John Newell-Price, Richard Ross, Charlotte Elder, Miguel Debono

    Design: Morning cortisol predicts the outcome of the short synacthen test (SST). There is a paucity of studies examining this in a dedicated cohort of children and adults weaning off glucocorticoids and using a modern immunoassay. This study aimed to identify early morning serum cortisol (EMC) cut-offs which predict the SST outcome in children and adults during glucocorticoid weaning. Methods: A retrospective cohort study of pediatric and adult patients on long-term glucocorticoids with suspected glucocorticoid-induced adrenal insufficiency (GIAI) undergoing an SST. Our main outcomes were cut offs with 95% and 99% sensitivity and specificity for EMC analysed on modern immunoassays, determined via receiver operating characteristic (ROC) curve analysis. A pass on SST was defined as 30-min cortisol of ≥430 nmol/L (15.6 µg/dL). Results: 151 and 372 SSTs were included in the pediatric and adult cohorts, respectively, of which 32% and 37% were passed. ROC curve analysis demonstrated that EMC performed well in both cohorts with area under curve (AUC) of 0.79 (95% CI, 0.71, 0.87) and 0.88 (95% CI, 0.84, 0.91), respectively. EMC cut offs to predict a pass on SST were 278 (10.1 µg/dL) and 290 nmol/L (10.5 µg/dL) at 95% sensitivity, and 316 (11.5 µg/dL) and 349 nmol/L (12.7 µg/dL) at 99% sensitivity, respectively. Further analysis in adults showed that using a 95% cut off in clinical practice was effective as 48/51 patients with EMC between 290 and 349 nmol/L (10.5-12.7 µg/dL), were weaned off without adverse events. Conclusion: Morning serum cortisol can predict the SST outcome in children and adults weaning from glucocorticoids. An EMC > 290 nmol/L in adults predicts a patient can stop glucocorticoid therapy and will recover adrenal function.

  • Open Access

    Randomised, placebo-controlled, double-blinded, four-way crossover trial to demonstrate the comparative pharmacodynamic equivalence of a non-invasive diagnostic test for adrenal insufficiency in a healthy population: the STARLIT-2 study protocol

    by Kathryn L Date, Kathleen Baster, Sharon L Caunt, Judith Cohen, Miguel Debono, Jane Fearnside, Trevor N Johnson, Richard J Ross, Rosie N Taylor, Charlotte J Elder

    Introduction Cortisol is an essential stress hormone and failure of its production, known as adrenal insufficiency (AI), is associated with significant mortality due to adrenal crisis. The Short Synacthen Test (SST) is the current diagnostic test of choice for AI, but it is both invasive and resource intensive. Globally, there is an unmet need for a non-invasive, cost-effective test. A novel formulation, Nasacthin, has been developed, which can be delivered intranasally, with the resultant glucocorticoid levels measured in saliva instead of blood. The Salivary Test of Adrenal Response to Liquid Intranasal Tetracosactide (STARLIT-2) study aims to clinically validate the Nasacthin test in healthy volunteers. Methods and analysis STARLIT-2 is a randomised, placebo-controlled, double-blinded, four-way crossover trial. 32 healthy adults and children will be randomised to receive each of four study drugs (Synacthen, Nasacthin and their respective placebos) over four study visits (one per visit). Paired blood and saliva samples will be collected from participants at baseline, and then at 30, 60, 90 and 120 min after drug administration. Additional salivary samples will be collected at 180, 240, 360 and 480 min after drug administration. The primary outcome measures are to compare the mean serum cortisol at 30 min after Synacthen or Nasacthin dose, with a view to determine non-inferiority; and to compare the mean change from baseline in serum cortisol at 30 min after active and placebo doses of both Synacthen and Nasacthin, aiming to demonstrate superiority of active over placebo. In addition, the proportion of participants for which Nasacthin produces a rise above a preset serum cortisol threshold at 30 min will be determined, with the negative per cent agreement with the SST calculated using the SST as the reference standard. Ethics and dissemination The study and its amendments have been reviewed and approved by South Central–Hampshire A Research Ethics Committee. Results will be disseminated in peer-reviewed journals and conference presentations, and feedback to trial participants will be facilitated following consultation with patient and public involvement and engagement groups. Trial registration number ISRCTN62724177


  • Open Access

    A Retrospective Study on Weaning Glucocorticoids and Recovery of the Hypothalamic–Pituitary–Adrenal Axis

    by Muhammad Fahad Arshad, Charlotte Elder, John Newell-Price, Richard Ross, Miguel Debono

    Context Glucocorticoids suppress the hypothalamic–pituitary–adrenal (HPA) axis, resulting in tertiary adrenal insufficiency (AI). When weaning patients off glucocorticoids there is no consensus on whether to maintain patients on prednisolone or convert to hydrocortisone. Objective To investigate HPA axis recovery in patients on long-term prednisolone and assess outcome after hydrocortisone conversion. Methods This was a retrospective cohort study at an outpatient endocrine steroid clinic. Patients were on long-term prednisolone and referred for HPA axis testing between 2015 and 2022. The main outcomes measured were (1) HPA axis recovery rate in patients on prednisolone demonstrated by a normal adrenocorticotrophic hormone (ACTH) stimulation test (AST) and (2) HPA axis recovery rate subanalysis of dose-matched patients with confirmed tertiary AI on prednisolone or hydrocortisone were measured. Results In total, 206 patients on prednisolone were tested for tertiary AI. Of these, 176 remained on prednisolone while 30 were converted to hydrocortisone. The overall HPA axis recovery rate for patients on prednisolone after interval testing was 137/206 (66.5%). The HPA axis recovery rate in dose-matched prednisolone and hydrocortisone conversion groups was 7/10 (70%) and 2/13 (15%) (P = .008), respectively. There was no difference in mean (SD) age (67.1 [12.2] vs 63.4 [11.1] years; P = .464) and baseline cortisol (5.3 [4.2] vs 4.6 [3.1] µg/dL; P = .648) and median [interquartile, IQR] glucocorticoid duration (1213 [1114] vs 2316 [4808] days; P = .693) and baseline ACTH (20.5 [29.0] vs 16.3 [14.8] ng/L; P = .905) between dose-matched prednisolone and hydrocortisone groups. Follow-up duration in the prednisolone group was significantly lower (median [IQR] 348 [975] vs 667 [884] days; P = .012). Conclusion Patients with glucocorticoid-induced AI maintained on once-daily prednisolone can recover HPA axis function when weaning. There is no apparent advantage to recover HPA axis function in converting to multiple-dosing hydrocortisone.


  • Open Access

    Multivariable Model to Predict an ACTH Stimulation Test to Diagnose Adrenal Insufficiency Using Previous Test Results

    by Neil Richard Lawrence, Muhammad Fahad Arshad, Riccardo Pofi, Sean Ashby, Jeremy Dawson, Jeremy W Tomlinson, John Newell-Price, Richard J Ross, Charlotte J Elder, Miguel Debono

    Context The adrenocorticotropin hormone stimulation test (AST) is used to diagnose adrenal insufficiency, and is often repeated in patients when monitoring recovery of the hypothalamo–pituitary–adrenal axis. Objective To develop and validate a prediction model that uses previous AST results with new baseline cortisol to predict the result of a new AST. Methods This was a retrospective, longitudinal cohort study in patients who had undergone at least 2 ASTs, using polynomial regression with backwards variable selection, at a Tertiary UK adult endocrinology center. Model was developed from 258 paired ASTs over 5 years in 175 adults (mean age 52.4 years, SD 16.4), then validated on data from 111 patients over 1 year (51.8, 17.5) from the same center, data collected after model development. Candidate prediction variables included previous test baseline adrenocorticotropin hormone (ACTH), previous test baseline and 30-minute cortisol, days between tests, and new baseline ACTH and cortisol used with calculated cortisol/ACTH ratios to assess 8 candidate predictors. The main outcome measure was a new test cortisol measured 30 minutes after Synacthen administration. Results Using 258 sequential ASTs from 175 patients for model development and 111 patient tests for model validation, previous baseline cortisol, previous 30-minute cortisol and new baseline cortisol were superior at predicting new 30-minute cortisol (R2 = 0.71 [0.49-0.93], area under the curve [AUC] = 0.97 [0.94-1.0]) than new baseline cortisol alone (R2 = 0.53 [0.22-0.84], AUC = 0.88 [0.81-0.95]). Conclusion Results of a previous AST can be objectively combined with new early-morning cortisol to predict the results of a new AST better than new early-morning cortisol alone. An online calculator is available at https://endocrinology.shinyapps.io/sheffield_sst_calculator/ for external validation.


  • Screening for adrenal insufficiency using home waking salivary cortisone is accurate and lowers NHS costs

    by Miguel Debono, Charlotte Elder, Jen Lewis, Richard Jacques, Sharon Caunt, Jane Fearnside, Simon Dixon, John Newell-Price, Martin Whitaker, Brian Keevil, et al.

    Introduction: The 250µg Short Synacthen test (SST) is the reference standard for a diagnosis of adrenal insufficiency (AI) in most endocrine centres. The test is expensive and time consuming, requiring clinic attendance. We hypothesised that a cheaper home waking salivary cortisone (WSC) is predictive of the SST 30-minute cortisol >430 nmol/l cut-off and carried out a diagnostic accuracy study to assess the predictive value of the WSC in diagnosing and excluding AI. We then carried out a cost analysis to compare two diagnostic strategies: the SST vs a two stage WSC±SST. Methods: We recruited 220 patients prospectively and all patients collected a WSC (measured by LC-MS/MS) and a SST was carried out on the same day. Using ROC curves we computed diagnostic accuracy and then estimated Positive (PPV) and Negative Predictive Value (NPV). A decision analytic model was developed to describe the costs and outcomes associated with the SST vs WSC±SST. To obtain a societal perspective we also enquired about patient costs and time off work via questionnaire. Results: The WSC was a strong predictor of the SST 30-minute serum cortisol >430 nmol/L: AuROC (95% CI), 95% (92,97%). Using a cut-off of ≥17 nmol/l one could exclude AI with a NPV 96% (90%,99%) and using a cut-off of <7 nmol/l one could confirm AI with a PPV 95% (87%,99%). Based on these values, using the WSC as a screening test would obviate the need for an SST in 70% of subjects. The economic results for the primary analysis show that a two-stage diagnostic strategy would save £102.83 in costs per patient. When using a societal perspective this strategy costs £126.99 less than current SST testing. Conclusions: WSC is an accurate screening tool for AI and significantly reduces costs for the NHS. Home WSC should be introduced to clinical care.

  • Open Access

    Rapid control of ectopic Cushing’s syndrome during the COVID-19 pandemic in a patient with chronic hypokalaemia

    by Ziadoon Faisal, Miguel Debono

    Summary In this case report, we describe the management of a patient who was admitted with an ectopic ACTH syndrome during the COVID pandemic with new-onset type 2 diabetes, neutrophilia and unexplained hypokalaemia. These three findings when combined should alert physicians to the potential presence of Cushing’s syndrome (CS). On admission, a quick diagnosis of CS was made based on clinical and biochemical features and the patient was treated urgently using high dose oral metyrapone thus allowing delays in surgery and rapidly improving the patient’s clinical condition. This resulted in the treatment of hyperglycaemia, hypokalaemia and hypertension reducing cardiovascular risk and likely risk for infection. Observing COVID-19 pandemic international guidelines to treat patients with CS has shown to be effective and offers endocrinologists an option to manage these patients adequately in difficult times. Learning points This case report highlights the importance of having a low threshold for suspicion and investigation for Cushing’s syndrome in a patient with neutrophilia and hypokalaemia, recently diagnosed with type 2 diabetes especially in someone with catabolic features of the disease irrespective of losing weight. It also supports the use of alternative methods of approaching the diagnosis and treatment of Cushing’s syndrome during a pandemic as indicated by international protocols designed specifically for managing this condition during Covid-19. Abstract Summary In this case report, we describe the management of a patient who was admitted with an ectopic ACTH syndrome during the COVID pandemic with new-onset type 2 diabetes, neutrophilia and unexplained hypokalaemia. These three findings when combined should alert physicians to the potential presence of Cushing’s syndrome (CS). On admission, a quick diagnosis of CS was made based on clinical and biochemical features and the patient was treated urgently using high dose oral metyrapone thus allowing delays in surgery and rapidly improving the patient’s clinical condition. This resulted in the treatment of hyperglycaemia, hypokalaemia and hypertension reducing cardiovascular risk and likely risk for infection. Observing COVID-19 pandemic international guidelines to treat patients with CS has shown to be effective and offers endocrinologists an option to manage these patients adequately in difficult times. Learning points This case report highlights the importance of having a low threshold for suspicion and investigation for Cushing’s syndrome in a patient with neutrophilia and hypokalaemia, recently diagnosed with type 2 diabetes especially in someone with catabolic features of the disease irrespective of losing weight. It also supports the use of alternative methods of approaching the diagnosis and treatment of Cushing’s syndrome during a pandemic as indicated by international protocols designed specifically for managing this condition during Covid-19.


  • Current and future treatment options for adrenal insufficiency

    by Muhammad Fahad Arshad, Miguel Debono

    Purpose of review: Patients with adrenal insufficiency (AI) irrespective of being on glucocorticoid replacement therapy still suffer from increased morbidity and mortality. A major contributing factor is an inability of conventional glucocorticoid treatment to mirror the physiological cortisol rhythm. Novel strategies to replicate the cortisol rhythm using hydrocortisone infusion pumps and oral modified release hydrocortisone have now been developed and confirmed to offer benefits to patients. Recent findings: In the DREAM study, when compared to multiple daily dosing of glucocorticoids Plenadren reduced weight, was less immunosuppressive and resulted in a better quality of life besides reducing infections. Chronocort that provides the early morning rise in cortisol improves androgen concentrations compared to conventional glucocorticoid treatments in congenital adrenal hyperplasia (CAH). Physiological hydrocortisone infusion pumps improve cortisol profiles with better adrenocorticotrophic hormone, glucose control, and quality of life (QOL) with androgen levels better controlled in CAH. Summary: Advances in glucocorticoid replacement for patients with AI are ongoing. Novel approaches to managing AI, enabled by this armamentarium of drug formulations, aims to improve patient health. Currently, their use should be reserved for patients with metabolic complications, very poor QOL and difficult-to-treat CAH. Larger studies based on outcomes are essential to understand to what extent these strategies can replace conventional treatments.


  • Steroid Replacement in Adrenal Insufficiency

    by Joanne C. Blair, Miguel Debono, Richard Ross